Amoytop Biotech Co., Ltd
Customers
0
None disclosed
Suppliers
1
0 disclosed
Latest period
Dec 31, 2023
10-K filed 2026-03-05
Suppliers 1
Companies that disclose Amoytop Biotech Co., Ltd as a major customer, as a share of their own revenue. 0 active, 1 lapsed.
| Company | % of their revenue | Est. $ from Amoytop Biotech Co., Ltd | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| ALGS Aligos Therapeutics, Inc. |
Named | — | FY 2023-12-31 | — | Lapsed Last seen 2023-12-31 |
10-K 2026-03-05 |
Revenue from contracts with customers Agreement with AmoytopIn May 2023, the Company and Amoytop Biotech Co., Ltd (Amoytop) entered into a Research Collaboration and Development Agreement (the Amoytop Agreement) with a focus on nucleic acid technology for HBV treatment, with the Company granting to Amoytop an exclusive, time-limited option to enter into an exclusive, territory-limited license to develop and commercialize such compounds. | ||||||
Alerts are coming
Get an email when Amoytop Biotech Co., Ltd's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.